Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT03570892. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
Study identification
- NCT ID
- NCT03570892
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 330 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 9, 2019 (Actual)
- Primary completion
- May 6, 2021 (Actual)
- Completion
- Feb 3, 2026 (Actual)
- Last update posted
- Jun 12, 2026
2019 – 2026
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moores UC San Diego Cancer Center | La Jolla | California | 92093 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| UCSF Medical Center | San Francisco | California | 94143 | — |
| Sarah Cannon Research Institute | Denver | Colorado | 80218 | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | — |
| Emory University | Atlanta | Georgia | 30329 | — |
| Uni of Chi Medi Ctr Hema and Onco | Chicago | Illinois | 60637 | — |
| University of Kansas Cancer Center | Kansas City | Kansas | 66205 | — |
| Wayne State University-Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Uni of Nebraska Med Ctr | Omaha | Nebraska | 68198 | — |
| Hackensack Uni Medical Center | Hackensack | New Jersey | 07601 | — |
| Jewish Hospital | Cincinnati | Ohio | 45236 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Oregon Health Sciences Univ | Portland | Oregon | 97239 | — |
| Uni Pennsylvania Abramson Cncr Ctr | Philadelphia | Pennsylvania | 19104 | — |
| MUSC Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Tennessee Oncology PLLC | Chattanooga | Tennessee | 37404 | — |
| St Davids South Austin Medical Ctr | Austin | Texas | 78704 | — |
| Texas Oncology-Baylor Scott and White | Dallas | Texas | 75231 | — |
| Uni of Texas MD Anderson Ca Center | Houston | Texas | 77030 | — |
| Methodist Hospital | San Antonio | Texas | 78229 | — |
| Uni of Wisconsin Carbone Cancer Ctr | Madison | Wisconsin | 53792-6164 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03570892, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03570892 live on ClinicalTrials.gov.